One such inhibitor is PXS-5055, which reduced LOX and LOXL-2 activity when administered to myelofibrosis patients that had developed a resistance to ruxolitinib in a phase 1 trial [32]. The gene discussed is LOXL2; the disease is myelofibrosis.